"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Descriptor ID |
D011565
|
| MeSH Number(s) |
C17.800.859.675
|
| Concept/Terms |
Pustulosis of Palms and Soles- Pustulosis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
|
Below are MeSH descriptors whose meaning is more general than "Psoriasis".
Below are MeSH descriptors whose meaning is more specific than "Psoriasis".
This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 1 | 3 |
| 1994 | 2 | 0 | 2 |
| 1996 | 1 | 3 | 4 |
| 1999 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 8 | 0 | 8 |
| 2004 | 5 | 0 | 5 |
| 2005 | 9 | 0 | 9 |
| 2006 | 9 | 0 | 9 |
| 2007 | 9 | 0 | 9 |
| 2008 | 9 | 1 | 10 |
| 2009 | 7 | 1 | 8 |
| 2010 | 8 | 1 | 9 |
| 2011 | 8 | 1 | 9 |
| 2012 | 6 | 2 | 8 |
| 2013 | 7 | 0 | 7 |
| 2014 | 8 | 0 | 8 |
| 2015 | 5 | 1 | 6 |
| 2016 | 12 | 1 | 13 |
| 2017 | 14 | 0 | 14 |
| 2018 | 22 | 0 | 22 |
| 2019 | 14 | 0 | 14 |
| 2020 | 13 | 1 | 14 |
| 2021 | 8 | 0 | 8 |
| 2022 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Psoriasis" by people in Profiles.
-
Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022 11; 14(16):1279-1290.
-
Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opin Biol Ther. 2022 12; 22(12):1489-1502.
-
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 10 04; 10(10):1167-1174.
-
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr?Evaluation of?TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51.
-
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
-
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 07 01; 158(7):735-744.
-
IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
-
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022 03; 186(3):466-475.
-
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
-
Probiotic supplementation improves clinical outcomes and quality of life indicators in patients with plaque psoriasis: A randomized double-blind clinical trial. Clin Nutr ESPEN. 2021 12; 46:33-39.